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Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer 
deaths. Cisplatin-based chemoradiotherapy is a standard of care for locally advanced 
disease. ATR and DNA-PK inhibition (DNA-PKi) are actively being investigated in clinical 
trials with preclinical data supporting clinical translation as radiosensitizers. Here, we 
hypothesized that targeting both ATR and DNA-PK with small molecule inhibitors would 
increase radiosensitization of HNSCC cell lines. Radiosensitization was assessed by Bliss 
independence analysis of colony survival data. Strong cell cycle perturbing effects were 
observed with ATR inhibition reversing the G2/M arrest observed for radiation-DNA-PKi. 
Increased apoptosis in combination groups was measured by Sub-G1 DNA populations. 
DNA-PKi increased radiation-induced RAD51 and gamma-H2Ax foci, with the addition 
of ATR inhibition reducing levels of both. A sharp increase in nuclear fragmentation 
after aberrant mitotic transit appears to be the main driver of decreased survival due 
to irradiation and dual ATR/DNA-PKi. Dual inhibition of DNA-PK and ATR represents a 
novel approach in combination with radiation, with efficacy appearing to be independent 
of p53 status. Due to toxicity concerns, careful assessment is necessary in any future 
translation of single or dual radiosensitization approaches. Ongoing clinical trials into 
the ATR inhibitor AZD6738 plus radiation, and the phenotypically similar combination of 
AZD6738 and the PARP inhibitor olaparib, are likely to be key in ascertaining the toxicity 
profile of such combinations.
Keywords: Dna damage response, radiosensitization, checkpoint abrogation, mitotic catastrophe, ataxia 
telangiectasia- and raD3-related
inTrODUcTiOn
In human cells, non-homologous end-joining (NHEJ) and homologous recombination (HR) are 
the major DNA double-strand breaks (DSBs) repair pathways, and defects in these pathways cause 
genome instability and promote tumorigenesis. DSBs can be formed (i) following exposure to 
ionizing radiation (X- or γ-rays) or genotoxic drugs, (ii) endogenously, during DNA replication, or 
(iii) as a consequence of reactive oxygen species generated during oxidative metabolism.
Radiotherapy is a standard of care for head and neck squamous cell carcinoma (HNSCC). The 
development of intensity-modulated radiotherapy has helped to spare normal tissues, such as the 
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parotid gland, from radiation-induced toxicity by more accura-
tely targeting head and neck tumors (1). While novel techniques, 
such as the image-guided MR-Linac, are entering trials (2), there 
are physical limits to significant further escalation of radiation 
doses due to normal tissue toxicity. Tumor-specific radiosensi-
tizers targeting DNA damage response (DDR) pathways represent 
a novel means to enhance the efficacy of radiotherapy.
The cell cycle phase in which the DSB occurs will determine 
the choice of the repair mechanism used by the cell (3, 4). NHEJ 
links the two ends of broken DNA by direct ligation and is active 
during all phases of the cell cycle, particularly during G0, G1, 
and early S phase. HR is most predominant during late S and 
G2 phases when a sister chromatid can be used as a template 
for repair.
The PI3-kinase like family of protein kinases includes ATM, 
ATR, and DNA-PKcs, which recruit DNA repair proteins and 
activate cell cycle checkpoints in response to DSBs (5). Most 
cancer cells are defective in the G1 checkpoint and, therefore, rely 
on their S/G2 checkpoints for survival following DNA damage. 
This may represent a means to specifically radiosensitize tumor 
cells. Of specific relevance to HNSCC is the loss of function of 
p53 by mutation, or degradation by E6 produced as a result of 
infection with high-risk human papillomavirus genotypes such 
as HPV16 (6, 7).
ATR, which initiates the S and G2 cell cycle checkpoint cas-
cade by phosphorylating CHK1, is an attractive target in cancer 
therapy. ATR acts as a key kinase in DDR signaling. DNA lesions 
which result in single-stranded DNA are coated by the protective 
replication protein A. ATR subsequently binds via the partner 
protein ATRIP. ATR acts both to stabilize stalled replication forks 
and to initiate downstream signaling via CHK1 leading to cell 
cycle arrest. A number of preclinical reports have demonstrated 
sensitization by ATR inhibitors to chemotherapy and radio-
therapy (8–12).
Two ATR inhibitors, such as VX-970 and AZD6738, are cur-
rently undergoing clinical evaluation. We are currently assessing 
safety of AZD6738 in a phase I clinical trial (PATRIOT), alone 
and in combination with radiotherapy (NCT02223923). Other 
trials are currently evaluating AZD6738 in combination with 
paclitaxel, carboplatin, olaparib, or durvalumab (NCT02630199, 
NCT02264678).
DNA-PK, a key component of the NHEJ pathway, correlates 
with decreased response to DNA-damaging agents and thera-
peutic resistance in multiple cancers (13–15). Furthermore, 
DNA-PK has also been implicated in other tumor-associated 
pro cesses, including genomic stability, hypoxia, inflammatory 
response, and transcription (16). Thus, the inhibition of DNA-PK 
is an attractive approach selectively to enhance DNA-damaging 
therapies. As such, DNA-PK has received significant attention 
from both industry and academia as a potential anticancer 
target. Many of the first identified DNA-PK inhibitors suffered 
from lack of specificity and poor pharmacokinetic properties, 
but more recently developed inhibitors, including NU7441 and 
KU-0060648, demonstrate improved specificity and pharmaceu-
tical properties (17) and have been used preclinically to explore 
the impact of DNA-PK inhibition (DNA-PKi) in multiple tumor 
types (18–20). In the clinic, two DNA-PK targeting molecules, 
such as CC-122 and CC-115, are currently being evaluated. CC-122 
is in a phase I clinical trial (NCT01421524) for solid tumors, 
non-Hodgkin lymphoma, and multiple myeloma. CC-115 is a 
dual inhibitor of DNA-PK and mTOR and is currently in phase I 
trial (NCT01353625) for advanced solid tumors and hematologic 
malignancies.
Considering that dysfunction of one DDR pathway may be 
compensated by another repair pathway (21) and contribute to 
resistance to DNA-damaging radiation and chemotherapies, we 
hypothesized that targeting both NHEJ and HR with small mol-
ecule inhibitors would enhance the radiosensitivity of tumor cells. 
Canonically, ATR is active during DNA replication in S phase, 
while repair by DNA-PK is utilized during non-replicative cell 
cycle phases such as G1. Inhibition of both targets simultaneously 
may overcome resistance in phases of the cell cycle where activity 
of each single target is lower or absent. We have previously shown 
that radiosensitization by AZD6738 is dependent on proliferation 
(8). We, therefore, used the ATR inhibitor, AZD6738, and the 
DNA-PK inhibitor, KU-0060648, and sought to identify favorable 
interactions between them. Due to the absence of available p53 
isogenic models for HNSCC, we used the isogenic HCT116 
p53+/+ and HCT116 p53−/− model to more conclusively study 
the role of p53 loss.
We demonstrate that AZD6738 and KU-0060648 both poten-
tiate the sensitivity to radiation as single agents and appear to be 
at least additive when combined together. Mechanistic analyses 
in vitro indicated reduced survival and a combined perturbation 
of cell cycle kinetics and DNA repair, resulting in severe nuclear 
fragmentation.
MaTerials anD MeThODs
cell culture conditions
LICR-LON-HN4 and LICR-LON-HN5 were a kind gift from 
Suzanne Eccles (The Institute of Cancer Research, Sutton, 
London, UK). HCT116 p53+/+ and p53−/− cells were obtained 
from Horizon Discovery (Cambridge, UK). Cells were cultured 
in DMEM (Invitrogen, Paisley, UK) supplemented with 10% 
FCS, 2  mM l-glutamine, and 1% penicillin/streptomycin at 
37°C with 5% CO2. Under these conditions, HCT116 and HN5 
cell lines dis played doubling times of 20–24  h, HN4 30–36  h. 
Cells were tested for Mycoplasma using the eMyco PCR kit from 
IntroBio (Seongnam-Si, South Korea) and authenticated by STR 
profiling (Bio-Synthesis Inc., TX, USA).
Drugs and irradiation
AZD6738 and KU-0060648 were kindly donated by AstraZeneca. 
Irradiation was carried out using an AGO 250 kV X-ray machine 
(AGO, Reading, UK).
survival assays
For MTT assays, cells were plated in 96-well plates and, after 
24 h, treated with AZD6738 and KU-0060648. Cell survival was 
measured 48 h after treatment by 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay according to the 
manufacturer’s instructions. Long-term survival in response to 
radiation was measured by colony formation assay. Cells were 
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seeded in 6-well dishes at appropriate densities. Cells were allowed 
to attach overnight. AZD6738 and KU-0060648 were added at 
the indicated concentrations 1 h before irradiation, drugs were 
not removed post-radiation. After 14 days, colonies were fixed 
and stained in 5% glutaraldehyde, 0.5% crystal violet, with colo-
nies containing more than 50 cells counted.
Western Blotting
Cells were plated in 10-cm dishes and allowed to attach overnight. 
AZD6738 and KU-0060648 were added at the indicated concen-
trations 1 h before irradiation. Medium and cells were harvested 
in PBS-containing 1 mM Na3VO4 and 1 mM NaF. Cells were pel-
leted before lysis in 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 
1% NP-40, 0.5% deoxycholate, and 0.1% SDS. Lysis supernatants 
were quantified by BCA assay from Pierce (Leicestershire, UK). 
Total protein lysate was separated by reducing SDS-PAGE, trans-
ferred to Midi Nitrocellulose membranes using a Transblot 
Turbo (Bio-Rad, Watford, UK), and blocked with TBS blocking 
buffer (Li-Cor Biotechnology, Cambridge, UK). Membranes were 
probed with antibodies specific for GAPDH clone 10C10, CHK1 
clone 2G1D5, phospho-CHK1 (S345) clone 133D3, DNA-PK code 
4602, γH2Ax (S139) clone 20E3 and Caspase 3 clone 8G10 from 
Cell Signaling (MA, USA); phospho-DNA-PK from Abcam 
ab18192 (Cambridge, UK); PARP clone F-2 was purchased from 
Santa Cruz (TX, USA).
cell cycle
Cells were plated in 10-cm dishes and allowed to attach over-
night. AZD6738 and KU-0060648 were added at the indicated 
concentrations 1  h before irradiation. Medium and cells were 
harvested at the desired time point after treatment and fixed 
overnight in ethanol. Cells were subsequently rehydrated in PBS 
and stained with propidium iodide and RNase solution from 
Cell Signaling (MA, USA). Cells were stained for mitotic index 
using anti-phospho-histone H3 (S10) AlexaFluor 647 from Cell 
Signaling (MA, USA). BrdU staining was performed by incubat-
ing cells with BrdU before collection and fixation in ethanol. Cells 
were subsequently stained using anti-BrdU antibody from Dako/
Agilent (Stockport, UK). Cells were analyzed on an LSR II from 
BD Biosciences (Oxford, UK).
confocal Microscopy
Cells were plated in 35-mm glass-bottomed dishes from Mattek 
(MA, USA) and allowed to attach overnight. AZD6738 and KU- 
0060648 were added 1 h before irradiation. Samples were fixed 
in 10% neutral buffered formalin, permeabilized in 0.2% Triton 
X-100, and treated with DNaseI from Roche (West Sussex, UK). 
Cells were blocked in 1% BSA, 2% FCS in PBS before stain-
ing using antibodies for γH2Ax (S139) clone 20E3 from Cell 
Signaling (MA, USA), or RAD51 clone 14B4 from Genetex 
(CA, USA) with goat anti-rabbit AlexaFluor 488 or goat anti-
mouse AlexaFluor 546 as secondary antibodies from Invitrogen 
(Paisley, UK). Nuclei were counterstained with DAPI. Samples 
were imaged using a Zeiss LSM710 inverted confocal microscope 
(Jena, Germany). Individual nuclei were scored manually for 
normal morphology, nuclear fragmentation such as micronuclei, 
or gross lobular irregularities. Nuclei were also scored for γH2Ax 
foci. >5 γH2Ax were scored as positive. Pan-nuclear γH2Ax 
staining was also scored if γH2Ax foci numbers were unquanti-
fiable. RAD51 and γH2Ax foci were also quantified by automated 
image quantification using Cell Profiler v2.2 (Broad Institute, 
CA, USA). Nuclei were segmented and counted based on DAPI 
staining, RAD51 and γH2Ax were counted and expressed as 
average foci per nucleus. Quantification of each independent 
experiment included approximately 100–300 nuclei.
statistical analysis
Drug interaction in Figure 1 was assessed by Bliss independence 
analysis using the equation Eexp = Ex + Ey − (ExEy) (22). E, in this 
case, represents cell kill from 0 to 1 with 1 being maximum cell 
kill. Eexp is the expected effect if two treatments are additive with 
Ex and Ey corresponding to the effect of each treatment indivi-
dually. ΔE = Eobserved − Eexp. Differences in observed vs expected 
cell kill is represented by ΔE ± 95% confidence intervals from 
observed data. Greater than expected cell kill is indicated by posi-
tive ΔE values, less than expected cell kill by negative ΔE values. 
In all other figures, unpaired two-tailed Student’s t-test was util-
ized for parametric analysis using Graphpad prism (version 7c).
resUlTs
aZD6738 and KU-0060648 combination 
results in improved radiosensitization
A 4 cell line panel was initially selected with two p53 mutant 
(p53mt) HNSCC cell lines, HN4 and HN5, tested alongside 
the p53+/+ and p53−/− isogenic HCT116 cell lines. The p53 
proficiency/deficiency of isogenic HCT116 cell lines has previ-
ously been validated in our lab by measuring p21 induction due 
to radiation (8). We first assessed cytotoxicity of AZD6738 and 
KU-0060648 alone or in combination by MTT over a range of 
doses (Figure 1A). IC50 doses of both AZD6738 and KU-0060648 
were broadly similar across the 4 cell line panel, ranging from 
1.5 to 4 and 0.5 to 1.5  µM, respectively. IC50 values used for 
combination MTT experiments in Figure 1A were found to be 
closer to IC25 and have been plotted as such. Bliss independence 
analysis was performed to determine if greater or less cell kill 
was observed vs calculated expected values when comparing dif-
ferent conditions. Bliss independence modeling indicated greater 
than expected cell kill to some degree at 0.5× or 1× IC25 values 
in a number of the cell lines, but less at other doses (Figure 1B). 
While both drugs are cytotoxic, rather than cytostatic, at higher 
concentrations and longer durations of exposure, the drop at 
these higher doses may be in part due to dynamic range limita-
tions of the MTT assay at the time point used.
The combination of AZD6738 and KU-0060648 was then 
assessed by clonogenic assay across a range of doses (Figure 1C) 
with Bliss independence analysis performed as per MTT data 
previously. These results showed no clear trend for greater or 
less observed cell kill between AZD6738 and KU-0060648 when 
measured by clonogenic assay.
The ability of AZD6738 and KU-0060648 to radiosensitize alone, 
or as a dual radiosensitizer drug combination vs single radiosen-
sitizer combinations was assessed by clonogenic assay (Figure 1E) 
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and Bliss independence analysis (Figure 1F). Bliss analysis indi-
cated that both AZD6738 and KU-0060648 alone acted as strong 
radiosensitizers in combination with radiation in all four cell lines. 
Greater than expected cell kill was observed in all cell lines for both 
the addition of AZD6738 to KU-0060648-radiation and the addi-
tion of KU-0060648 to AZD6738-radiation. Similar results were 
observed across a range of drug doses (complete data shown in 
Figure S1 in Supplemen tary Material). For 125 + 125 nM of each 
drug (250 nM combined) the radiosensitization effect observed is 
of equal potency to that observed for 500 nM of each drug alone 
(Figure 1G). This may present an opportunity for a reduced com-
bined drug dose clinically. Combination of both drugs at 125 nM 
GFigUre 1 | DNA-PK inhibition enhances radiosensitization when added to ATR inhibition and radiation. (a) The combination of the ATR inhibitor AZD6738 and the 
DNA-PK inhibitor KU-0060648 was assessed by first determining cell viability 48 h after treatment by MTT analysis at 0.25×, 0.5×, 1×, 2×, and 4× IC50 doses. 
Dose–response curves were used initially to derive the following IC50 doses. For AZD6738, HN4, 1.5 µM; HN5, 1.5 µM; HCT116 p53+/+, 3.0 µM; and HCT116 
p53−/−, 4.0 µM. For KU-0060648, HN4, 0.8 µM; HN5, 0.5 µM; HCT116 p53+/+, 1.5 µM; and HCT116 p53−/−, 1.5 µM. In subsequent combination experiments, 
these doses proved to be approximately IC25 doses and have been presented accordingly for accuracy. (B) Observed cell kill vs expected cell kill was determined by 
Bliss independence analysis. For example, ×1 IC50 + ×1 IC50 is the observed toxicity of this combination (expressed as 0 to 1 with 1 being maximum kill), minus the 
calculated “expected” effect if the individual values for ×1 IC50 AZD6738 and ×1 IC50 KU0060648 were expected to combine without any interaction. A positive ΔE 
corresponds to greater observed kill than expected for non-interacting combinations. Negative ΔE indicates less than expected cell kill. Further details outlined in the 
statistical analysis section of the methods. Greater than expected cell kill is indicated by ΔE and 95% confidence intervals (CIs) from observed data falling all above 
zero; less than expected cell kill where all values fall below zero. (c) Clonogenic survival was determined for AZD6738 and KU-0060648 alone and in combination 
across a range of doses. Values expressed as surviving fraction relative to untreated control. (D) Bliss analysis as described in panel (B). (e) Clonogenic survival was 
determined for combinations of AZD6738, KU-0060648, and 2 Gy radiation. Values expressed as surviving fraction relative to untreated control. (F) Bliss analysis as 
described in panel (B). (g) Comparison plots of the combination of 125 nM each of AZD6738 and KU0060648 vs 250 or 500 nM of individual drugs and the 
corresponding radiosensitization effect by clonogenics. All panels represent a minimum of three independent experiments ±SEM, except Bliss analysis in (B,D,F) 
where error bars are ±95% CIs. Statistical analysis performed between indicated conditions by unpaired t-test *P < 0.05.
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in the absence of radiation appears to have a lower toxicity vs single 
500  nM doses, though this was only statistically significant for 
AZD6738. Combining both drugs at 125 nM had a stronger radio-
sensitization effect than either drug individually at 250 nM. These 
data are suggestive of potentially greater than additive effects.
Clonogenic assays may better represent the effect of DDR 
inhibitors alone or in combination with radiation when compared 
with MTT assay due to their long-term nature. While short-term 
MTT observations will be dominated by cell cycle-linked effects, 
such as death due to replicative stress or mitotic catastrophe, 
long-term clonogenic assays will also include toxicity as a con-
sequence of misrepair of DNA damage. The results observed 
give a rationale for testing AZD6738 and KU-0060648 as a dual 
radiosensitizer treatment. Drug-on-target modulation of CHK1 
on Ser345 and DNA-PK on Ser2056 was observed by Western 
blot (Figure 2). A clear reduction in radiation-induced Ser345 
CHK1 downstream of ATR was observed starting at 30–100 nM 
AZD6738 concentrations. Ser2056 is an autophosphorylation site 
of DNA-PKcs which has previously been shown to be reduced by 
DNA-PKcs kinase inhibition (23). Clear inhibition was observed 
at 1 h post-radiation at concentrations greater than 100 nM.
aZD6738 and KU-0060648 Modulate cell 
cycle Progression after radiation
We further evaluated the impact of ATR, DNA-PKi, and irradia-
tion on cell cycle distribution. Active DNA synthesis was meas-
ured by BrdU incorporation (Figure 3A). Variable reduction in 
BrdU incorporation was seen in all cell lines due to AZD6738, 
KU-0060648, or radiation monotherapy treatments at 24 h. The 
most significant reduction observed was due to the combination 
of radiation and KU-0060648. AZD6738 addition to radiation 
alone or radiation-KU-0060648 combined, did not appear to 
alter BrdU incorporation apart from a small increase observed in 
HCT116 p53+/+ (Figure 3A).
Cell cycle analysis by propidium iodide (Figure 3B) or meas-
urement of the mitotic index by phospho-HistoneH3 (Figure 3C) 
was also performed. At 24 h, compared to radiation, AZD6738-
radiation, or KU-0060648-radiation, the triple combination of 
AZD6738, KU-0060648, and radiation resulted in a significant 
increase in cells in G1 at the expense of S/G2. This was particularly 
marked for the addition of AZD6738 to KU-0060648-radiation. 
KU-0060648 induced a significant G2/M population increase 
when added to radiation, which was abrogated by the addition 
of AZD6738. Phospho-histoneH3 (Figure  3C) data at 6  h did 
not indicate any significant modulation of the mitotic index by 
KU-0060648, while AZD6738 abrogated any radiation-induced 
decrease in mitotic index. A lower mitotic index was observed 
in HN5 cell lines at 24 h in conditions containing KU-0060648. 
However, no other clear patterns could be identified except for an 
elevated mitotic index across conditions containing AZD6738.
The combination of aZD6738 and KU-
0060648 With radiation increases the 
sub-g1 Population
We further evaluated whether reduced survival and alterations 
to cell cycle progression corresponded to apoptotic cell death 
FigUre 2 | DNA-PK inhibition and ATR inhibition modulate DNA damage response signaling. (a) Western blot indicates AZD6738 inhibition of ATR through loss of 
downstream phosphorylation of CHK1 on Ser345. Dose escalation of AZD6738 with 4 Gy radiation, samples collected 1 h post-radiation. (B) Modulation of 
DNA-PK phosphorylation by KU-0060648 was shown by Western blot in HCT116 p53+/+ and p53−/− cell lines. Dose escalation of KU-0060648 with 10 Gy 
radiation, samples collected 1 h post-radiation.
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by measuring caspase-3, PARP cleavage, and γH2Ax levels at 
48  h post-treatment (Figure  4A). AZD6738 and KU-0060648 
as single agents did not, or only slightly, induced caspase-3 or 
PARP cleavage in all cells. The combination of AZD6738 and 
radiation induced a substantial increase in cleaved caspase-3 
or cleaved PARP across all cell lines. Interestingly, KU-0060648 
plus radiation, despite profound radiosensitization in clonogenic 
assays, did not result in increased PARP and caspase-3 cleav-
age. The addition of KU-0060648 resulted in no increase, or in 
some cases a decrease, in the cleavage observed when added to 
AZD6738-radiation. The addition of KU-0060648 did result in a 
clear decrease in γH2Ax signal in all cell lines tested (Figure 4A). 
This has previously been shown to indicate DNA-PKcs kinase 
inhibition (24) and as a clear sign of drug-on-target effect at the 
250 nM dose used.
Analysis of DNA fragmentation and sub-G1 populations was 
carried out by propidium iodide cell cycle analysis (Figure 4B). 
This did reveal an increase in the sub-G1 population due to the 
addition of KU-0060648 to AZD6738-radiation which was par-
ticularly clear for HCT116 p53+/+ and p53−/− cell lines.
aZD6738 reduces raD51 and γh2aX  
Foci Formation induced by KU-0060648-
radiation resulting in increased  
nuclear Fragmentation
To verify the ability of AZD6738 and KU-0060648 to abrogate 
radiation-induced DSB repair and prevent Rad51-mediated HR, 
we quantified the formation of γH2Ax and Rad51 foci in HCT116 
p53+/+ and p53−/− cells.
Quantification of γH2Ax images classified nuclei as normal 
or abnormal in morphology with further sub-classification based 
on focal- or pan-γH2Ax staining (Figure 5A). Automated image 
quantification of γH2Ax was also performed at 4 and 24 h (Figure S2 
in Supplementary Material). Data at 4  h were variable with no 
clear definitive changes apart from a trend for reduced radiation-
induced γH2Ax due to the addition of AZD6738. At 24 h, there was 
some evidence that KU-0060648 may increase residual γH2Ax 
foci. At 24 h, AZD6738 reduced radiation-induced γH2Ax focus 
formation from both radiation alone and KU-0060648-radiation 
conditions. This was statistically significant in three out of four 
conditions where AZD6738 was added to radiation or radiation 
plus KU-0060648 (Figure S2 in Supplementary Material).
RAD51 images were analyzed at 4 and 24  h by automated 
image quantification. RAD51 focus formation is presented as the 
average number of foci per nucleus for each condition (Figure 5B). 
KU-0060648 at 24 h significantly increased levels of radiation-
induced RAD51 foci in both cell lines. The addition of AZD6738 to 
radiation alone or KU-0060648-radiation strongly reduced Rad51 
focus formation at both 4 and 24  h. The reduction in percen-
tage of RAD51-positive cells observed at 4  h post-radiation is 
significantly greater than the reduction in S-phase possible over 
such a short time scale. However, at 24 h, the S-phase reduction 
as observed by BrdU staining for radiation and KU-0060648 
(Figure  3A) indicates this may be a contributing factor to the 
drop in RAD51 under these conditions. This, however, was not 
the case for AZD6738 and radiation at 24 h as BrdU-positive cells 
maintained broadly similar levels to those of controls.
At 24  h, the addition of AZD6738 to radiation alone or 
KU-0060648-radiation manifests as an increase in nuclei classi-
fied as abnormal (Figure 5A). At 48 h, the total number of abnormal 
nuclei is similar between these two conditions, with the major 
difference being a substantial reduction in γH2Ax foci present 
due to the addition of AZD6738 to KU-0060648-radiation.
AB
C
FigUre 3 | Modulation of the cell cycle by DNA-PK inhibition and ATR inhibition in combination with radiation. (a) FACS analysis of BrdU incorporation was used to 
assess active DNA synthesis in response to AZD6738, KU-0060648, and 4 Gy radiation combinations at 24 h post-radiation. Values expressed relative to control. 
(B) Cell cycle profiles at 24 h were assessed by staining for DNA content using propidium iodide in response to AZD6738, KU-0060648, and 4 Gy radiation 
combinations. (c) Cells in mitosis positive for phospho-histone H3 were quantified by FACS. Quantification was performed at 6 and 24 h in response to AZD6738, 
KU-0060648, and 4 Gy radiation combinations. All panels represent a minimum of three independent experiments ± SEM, except HN5 in (a) which is n = 2. 
Statistical analysis performed between indicated conditions by unpaired t-test *P < 0.05.
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DiscUssiOn
A number of DDR inhibitors have been extensively explored in 
preclinical studies. More recent DDR-targeting compounds have 
looked to exploit the high prevalence of a defective G1/S check-
point in cancer cells compared with normal tissue. This has given 
rise to G2/M checkpoint-targeting agents such as ATR and CHK1 
inhibitors. It has been hypothesized that maximal clinical efficacy 
of these agents is likely to be found in combination with exogenous 
DNA damage sources. Due to its position as a first-line treatment 
for HNSCC and many other cancers, radiation is a highly favorable 
source of this damage. A defective G1/S checkpoint through loss of 
function of p53 due to mutation or E6-mediated protein degradation 
by HPV infection is highly prevalent in HNSCC. We sought to bet-
ter understand the role of p53 loss in determining radiosensitization 
by the combination of ATR and DNA-PK inhibitors.
Preclinical validation of both CHK1 inhibition (CHK1i) and 
ATR inhibition (ATRi) has shown them to be proficient radiosen-
sitizers (8, 25–27). While ATRi and CHK1i have been shown to 
interfere with cell cycle arrest and HR, cancer cells may resort to 
alternative repair mechanisms such as NHEJ. While more error 
prone, this may present a mechanism capable of reducing the 
efficacy of ATRi in combination with radiation. For this reason, 
we sought to investigate if dual ATR and NHEJ inhibition, via 
DNA-PKi, was more effective in combination with radiation than 
ATRi alone.
AB
FigUre 4 | Apoptotic signaling in response to DNA-PK inhibition and ATR inhibition in combination with radiation. (a) Western blot analysis was used to assess 
levels of H2Ax phosphorylation on Ser139, and apoptosis was identified by cleaved caspase 3 and cleaved PARP. Cell lysates were harvested at 48 h after radiation 
with AZD6738 and KU-0060648 addition 1 h before radiation. (B) Sub-G1 cells were identified at 24 and 48 h by propidium iodide staining and FACS in response to 
AZD6738, KU-0060648, and 4 Gy radiation combinations. Data represent a minimum of three independent experiments ± SEM. Statistical analysis performed 
between indicated conditions by unpaired t-test *P < 0.05.
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The addition of ATRi to DNA-PKi-radiation or DNA-PKi to 
ATRi-radiation was shown to have the highest radiosensitization 
effect. This comparison includes the effect of radiosensitization 
with individual drugs combined with radiation. This is particu-
larly compelling as both ATRi and DNA-PKi alone act as strong 
radiosensitizers, yet Bliss independence analysis suggests greater 
than expected cell kill was still possible with a second mechanis-
tically independent DDR inhibitor.
Mechanistic data suggest the increased efficacy of dual ATRi 
and DNA-PKi in combination with radiation is based on both 
modulation to DNA repair focus formation and the resulting 
downstream nuclear fragmentation. DNA-PKi increased both 
RAD51 and γH2Ax focus formation after radiation. Interestingly, 
total γH2Ax phosphorylation decreased due to DNA-PKi in 
Western blots. This may indicate an increase in the number of 
unresolved DSBs and a reduction in the γH2Ax signal flanking 
the break site.
The appearance of large amounts of γH2Ax alongside cas-
pase 3 or colocalization with TUNEL has been shown to be an 
apoptotic signal rather than DNA repair foci (28, 29). However, 
this does not appear to be the case as the addition of DNA-PKi 
reduces H2Ax by Western blot, though paradoxically clearly 
leads to increased γH2Ax foci (Figure 5). Foci and total γH2Ax 
appear to not be interchangeable measures of DNA DSBs. There 
may be more breaks but less extensive phosphorylation flanking 
the break site. Increased sub-G1 populations with the triple 
combination, despite no increase in cleaved caspase 3 or cleaved 
PARP, suggest a caspase-independent mechanism might be 
responsible for increased cell death. Mitotic catastrophe induced 
by paclitaxel in HCT116 was shown to increase sub-G1 popula-
tions in a caspase-independent manner (30). Loss of BUB1 leads 
to caspase-independent mitotic death due to treatment with the 
HSP90 inhibitor 17AAG (31). Due to the role of ATR as a cell 
cycle checkpoint, it is not unexpected that cell death may be, in 
part, driven by caspase-independent mitotic catastrophe.
The ability of ATR or CHK1i to abrogate G2 arrest and decrease 
RAD51 focus formation is well established. Mutations or DDR 
inhibitors that increase dependency on HR or G2 arrest are likely 
to combine favorably with ATR inhibition. This has proven to be 
the case with PARP inhibition (PARPi) which displays syner-
gistic activity in combination with ATRi in BRCA-mutant ovarian 
(32, 33), SLFN11-negative prostate, leukemia, and Ewing’s sar-
coma cell lines (34) as well as in HR-proficient cell lines (35). 
ATRi has also been shown to be synthetically lethal with ARID1A 
loss (36). ATRi in combination with PARPi leads to chromosome 
fragmentation as measured by chromatid breaks on metaphase 
spreads (32). ATRi in ARID1A−/− cells increases anaphase 
bridge formation and chromatid fragmentation on metaphase 
spreads (36). In this regard, our data on ATRi and DNA-PKi are 
phenotypically similar to that observed for both ARID1A loss 
and PARPi in combination with ATRi.
A sharp increase in nuclear fragmentation after aberrant 
mitotic transit appears to be a common finding when the ATR-
CHK1 signaling pathway is disrupted in radiation combination 
AB
FigUre 5 | Continued
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CFigUre 5 | Modulation of H2Ax and RAD51 DNA repair focus formation by DNA-PK inhibition and ATR inhibition in combination with radiation. (a) Nuclear γH2Ax 
was imaged by confocal microscopy. Fixed samples were collected at the time points and treatments indicated in HCT116 p53+/+ and p53−/− isogenic cell lines. 
Nuclei were classified as having normal circular morphology or the presence of clear nuclear fragmentation such as micronuclei. A nucleus with multiple fragments 
was only scored as a single fragmented nucleus. Nuclei were further subclassified as having no γH2Ax, >5 γH2Ax foci, or having an unquantifiable level of γH2Ax 
staining referred to pan-γH2Ax positive staining. Example images of scoring are shown. Scale bar equals 10 µM with all images shown at the same magnification. 
DAPI used as nuclear counterstain. Data represent a minimum of three independent experiments ± SEM. Example images of scoring criteria are also shown.  
(B) RAD51 foci were imaged by confocal microscopy. RAD51 and nuclei were quantified by automated image quantification and expressed as the average RAD51 
foci per nucleus. Data represent a minimum of two independent experiments at 4 h and three at 24 h ± SEM. Statistical analysis performed between indicated 
conditions by unpaired t-test *P < 0.05. (c) Larger example images of γH2Ax (green staining) and RAD51 (red staining), respectively, quantified in panels (a,B).
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studies (8, 37, 38). ATR plays a key role in the accumulation of 
ribonucleotide reductase subunit 2 and origin firing in S-phase. 
In early S-phase cells, ATRi can induce massive ssDNA accumula-
tion, but later S-phase cells have been shown to trigger a DNA- 
PK- and CHK1-mediated backup pathway which suppresses 
origin firing (39). ATR has been shown to be critical for preven-
ting nuclease cleavage of replication forks and severe nuclear 
fragmentation due to replication catastrophe (40–42). It is pro b-
able that dual inhibition of DNA-PK and ATR increases this phe-
nomenon, manifesting as the increased nuclear fragmentation 
observed. Micronuclei generated as a result of nuclear fragmen-
tation have been identified as displaying reduced replication and 
increased DNA damage during S-phase, as well as showing cell 
cycle dyssynchrony (8, 43). This is believed to be due to reduced 
nuclear import vs the primary nucleus or rupturing of the nuclear 
membrane (43, 44).
Previously published data have shown the ATR inhibitor 
AZD6738 is well tolerated at active doses in  vivo in DNA-PK-
deficient NOD scid gamma mice (8). Our data here show com-
bined DNA-PKi and ATRi does not display obvious combined 
toxicity by clonogenic assay, with enhanced cell kill effects only 
observed due to the addition of radiation. This was most clearly 
illustrated by the ability of combining both drugs at 125  nM 
showing similar radiosensitization capability to each drug alone 
at the much higher dose of 500 nM. Taken together, these data 
may suggest a window for relative therapeutic benefit vs normal 
tissue outside the radiation field. G1/S checkpoint activation has 
been shown to occur slowly after radiation, in contrast to rapid 
activation of the G2/M checkpoint (45). Previous work in our 
lab on AZD6738 and radiation (8) has shown that S-phase or 
mitotic transition appears essential for radiosensitization activity. 
Tumor cells proficient in p53, such as HCT116, still readily enter 
and transit these phases of the cell cycle, and still do so for some 
time post-radiation. Non-proliferating normal tissue in G0/G1 
represents a distinct p53-competent population not subject to 
the cell cycle-linked effects of radiation and ATRi in particular. 
Preclinical studies of AZD6738 in combination with olaparib 
in vivo have reported efficacy without weight loss compared with 
control groups (32). Of particular relevance to HNSCC will be 
any reports of worsening acute toxicities, such as oral mucositis, 
in preclinical and clinical studies since proliferative epithelial 
cells are likely to be the most sensitive normal cells within the 
radiation field to radiosensitizers. Careful assessment of normal 
tissue toxicities will be required for the entire class of radiosensi-
tizers, especially in regard to normal, but proliferating, irradiated 
cells. In light of the similar phenotype observed, an open and 
recruiting clinical trial (NCT02264678) investigating the ATR 
and PARP inhibitors, AZD6738 and olaparib may help to inform 
any future studies into ATRi and DNA-PKi on both efficacy and 
any toxicity issues.
In summary, dual inhibition of DNA-PK and ATR represents 
a promising approach in combination with radiation. This 
combination appears to share mechanistic similarity with PARPi 
in combination with ATR inhibition. However, the evidence 
suggests dual ATRi and DNA-PKi driven radiosensitization is 
broadly similar irrespective of p53 status.
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